Roivant Sciences (ROIV) revenue: $8.3M
Roivant Sciences reported $8.3M of revenue for the year ended Mar 31, 2026, down 71.6% from $29.1M a year earlier.
From Roivant Sciences's filings with the SEC · Read the filing · ROIV stock page
Roivant Sciences revenue by year
#3,253 of 3,622 US companies by revenue · See the full ranking
| Year ended | Revenue | Change |
|---|---|---|
| Mar 31, 2026 | $8.3M | -72% |
| Mar 31, 2025 | $29.1M | -11% |
| Mar 31, 2024 | $32.7M | +4% |
| Mar 31, 2023 | $31.5M | -43% |
| Mar 31, 2022 | $55.3M | – |
Revenue of similar companies
Companies in the same industry as Roivant Sciences, by SEC industry code, with the closest revenue. Each name opens the same page for that company.
| Company | Revenue, latest year | Year ended |
|---|---|---|
| Zenas BioPharma | $10M | Dec 31, 2025 |
| Janux Therapeutics | $10M | Dec 31, 2025 |
| Precigen | $9.7M | Dec 31, 2025 |
| Roivant Sciences | $8.3M | Mar 31, 2026 |
| Xenon Pharmaceuticals | $7.5M | Dec 31, 2025 |
| Immunome | $6.9M | Dec 31, 2025 |
| InMed Pharmaceuticals | $4.9M | Jun 30, 2025 |
Questions and answers
What is Roivant Sciences's revenue?
Roivant Sciences reported $8.3M of revenue for the year ended Mar 31, 2026, down 71.6% from $29.1M a year earlier.
Numbers as reported in Roivant Sciences's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology